In HER2+ breast cancer, the combination of palbociclib and trastuzumab (anti-HER2) achieves anti-tumor efficacy by stimulating the release of CXCR3-reactive chemokines and increasing the recruitment of tumor-associated natural killer (NK) cells (259). Here, ERBB2 is linked to breast cancer.